echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: A randomized clinical trial study of TARGIT-IORT (targeted intraoperative radiotherapy during breast cancer lumpectomy)

    Br J Cancer: A randomized clinical trial study of TARGIT-IORT (targeted intraoperative radiotherapy during breast cancer lumpectomy)

    • Last Update: 2021-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Most breast cancer patients are generally suitable for breast-conserving surgery and adjuvant radiotherapy, rather than total mastectomy.


    Breast cancer researchers proposed the concept of TARGeted intraoperative radiotherapy (TARGIT-IORT).


    The TARGIT-IORT trial aims to achieve accurate positioning and rapid formation of tumor focus radiotherapy strategies , which only focus on target tissues, so that normal tissues and organs (such as heart, lung, skin and chest wall structures) are protected from unnecessary and potential Destructive radiation therapy.


    TARGIT-IORT trial aims to achieve accurate positioning and rapid formation of tumor focal radiotherapy strategies TARGIT-IORT trial aims to achieve accurate positioning and rapid formation of tumor focal radiotherapy strategies

    Researchers designed a randomized trial of TARGIT-A.


    Targeted intraoperative radiotherapy (TARGIT-IORT), which is risk-adapted during breast cancer lumpectomy, is as effective as total breast external beam radiotherapy (EBRT).



    Forest plot shows the local recurrence-free survival rate and overall survival rate of tumor subgroups

    Forest plot shows the local recurrence-free survival rate and overall survival rate of tumor subgroups

    The results showed that there was no difference in the local recurrence-free survival rate between TARGIT-IORT and EBRT in each tumor subgroup.


    Unlike the EBRT group, the local recurrence rate in the TARGIT-IORT group is not a higher predictor of the remote recurrence rate or the risk of death.



    Subgroup analysis of the overall survival rate of cancer patients of each grade

    Subgroup analysis of the overall survival rate of cancer patients of each grade

    All in all, the results of the study revealed that in all subgroups, TARGIT-IORT was as effective as the EBRT treatment strategy.


    The results of the study revealed that in all subgroups, TARGIT-IORT was as effective as the EBRT treatment strategy.



    org/10.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.